Sign in
CHMA Stock Price, Chart, Stats & News
Chiasma, Inc.
Save
Chiasma, Inc. (CHMA) does not currently pay a dividend.
–
Market cap
–
Current P/E
–
Forward P/E
CHMA chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 94.48% |
Operating margin | -6387.79% |
Pretax margin | -6753.62% |
Net margin | -6761.21% |
Effective tax rate | -0.11% |
ROA | -42.41% |
ROE | -84.23% |
D/E | – |
Interest coverage ratio | -12.03x |
CHMA valuation
P/E | – |
P/S | – |
P/B | 2.14x |
P/CF | -2.61x |
P/FCF | – |
P/OCF | -2.61x |
PEG | -0.03x |
EV multiple | -0.23x |
About
Chiasma, Inc. is a biopharmaceutical company in the advanced stages of clinical development, specializing in oral drug formulations. The company utilizes its Transient Permeability Enhancer (TPE) technology platform to develop treatments for rare and serious chronic conditions on a global scale. A key product in its pipeline is MYCAPSSA, an oral octreotide capsule currently in Phase III clinical trials.
Similar securities
Based on sector and market capitalization
Report issue